BD - I am not an oncologist or in biotech but I will post my observation.
Keytruda is a Pd-1 checkpoint inhibitor, they block mechanism that tumors use to protect themselves from being attack by immune cells.
Two receptors protecting cancer cells , so in order for immune response to happen at least one need to be block.
Pd-1 receptor is located on T cell.
Pd-L1 receptor is located on the cancer cells.
Keytruda blocking Pd-1 and then T cells start to recognize cancer and attack it.
Some like Tecentrig ( atezolizumab ) blocking Pd-L1 on the cancer cells with the same results.
Immune system start to attack cancer , side effects are that sometimes immune system becomes over active attacking healthy organs.
Lacrotrectinid ( Vitrakivi ) works differently , it is inhibitor of tropomysis kinase receptors TrkA, TrkB , TrkC ...( also know as high affinity nerve growth factor receptor , neurotrophic tyrosine kinase receptor
Receptor tyrosine kinase regulate cellular growth and differentiation during development.
In some cancers there is deregulation of tyrosine kinase function with production of different cancers.
Then when inhibitor of tropomysis kinase receptor may help .
It will be mostly use for non-responding cancers because of very severe side effects,
like :
- possibly fatal cardiac dysfunction
- kidney failure.
- Liver failure
- Gastrointestinal perforation
- bleeding
- Thyroid abnormality
- pneumonia
- neurological problems
and many others...
Leronlimab doesnt really cure cancer but prevent spreading of CCR5 positive cancers .
I believe that very often it will be use together with other cancer treatment,
As per dr RP patients will need much lower dose of chemotherapy since efficacy of chemotherapy is about 250% stronger when use with Leronlimab.
I will also like to hear others opinions.
-
